Surrogate markers of resectability in patients undergoing exploration of potentially resectable pancreatic adenocarcinoma

Journal of Gastrointestinal Surgery

Volumn 12, Issue 6, 2008, Pages 1068-1073

  Ong, S L ^a   Garcea, G ^a   Thomasset, S C ^a   Mann, C D ^a   Neal, C P ^a   Abu Amara, M ^a   Dennison, A R ^a   Berry, D P ^a  

^a LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

Bilirubin; CA19.9; Inflammatory markers; Lymphocyte; Neutrophil; Pancreatic cancer; Platelet; Resectability

Indexed keywords

CA 19-9 ANTIGEN; TUMOR MARKER; UREA;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BIOPSY; BLOOD; CANCER STAGING; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DECISION MAKING; ENDOSCOPIC ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LAPAROSCOPY; MALE; METHODOLOGY; MIDDLE AGED; PANCREAS TUMOR; PANCREATICODUODENECTOMY; PROGNOSIS; RETROSPECTIVE STUDY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CA-19-9 ANTIGEN; DECISION MAKING; ENDOSONOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LAPAROSCOPY; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROGNOSIS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL; UREA;

EID: 43249111090     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-007-0422-6     Document Type: Article

References (25)

1. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363:1049-1057.
2. Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: Pathology, complications, and outcomes. Ann Surg 1997;226:248-257.
3. Garcea G, Dennison AR, Ong SL, Pattenden CJ, Neal CP, Sutton CD, Mann CD, Berry DP. Tumour characteristics predictive of survival following resection for ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol 2007;33:892-897.
4. Zacharias T, Jaeck D, Oussoultzoglow E, Neuville A, Bachellier P. Impact of lymph node involvement on long-term survival after R0 pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas. J Gastrointest Surg 2007;11(3):350-356.
5. Soriano A, Castells A, Ayuso C, Ayuso JR, de Caralt MT, Gines MA, Real MI, Gilabert R, Quinto L, Trilla A, Feu F, Montanya X, Fernandez-Cruz L, Navarro S. Preoperative staging and tumor resectability assessment of pancreatic cancer: Prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging and angiography. Am J Gastroenterol 2004;99(3):492-501.
6. Camacho D, Reichenbach D, Guerr GD, Venema TL, Sweeney JF, Fisher WE. Value of laparoscopy in the staging of pancreatic cancer. JOP 2005;6(6):552-561.
7. Long EE, Van Dam J, Weinstein S, Jeffrey B, Desser T, Norton JA. Computed tomography, endoscopic, laparoscopic, and intra-operative sonography for assessing resectability of pancreatic cancer. Surg Oncol 2005;14(2):105-113.
8. Kilic M, Gocmen E, Tez M, Ertan T, Keskek M, Koc M. Value of preoperative serum CA 19.9 levels in predicting resectability for pancreatic cancer. Can J Surg 2006;49(4):241-244.
9. Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 2003;138(9):951-955.
10. Karachristos A, Scarmeas N, Hoffman JP. CA19.9 levels predict results of staging laparoscopy in pancreatic cancer. J Gastrointest Surg 2005;9(9):1286-1292.
11. Tian F, Appert HE, Myles J, Howard JM. Prognostic value of serum CA19.9 levels in pancreatic adenocarcinoma. Ann Surg 1992;215(4):350-355.
12. Lowe D, Lee J, Schade R, Chaudhary A. Patient with markedly elevated CA19.9 not associated with malignancy. South Med J 2006;99(3):306-308.
13. Mann DV, Edwards R, Ho S, Lau WY, Glazer G. Elevated tumour marker CA19.9: Clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000;26(5):474-479.
14. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil- lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005;91(3):181-184.
15. Cook EJ, Walsh SR, Farooq N, Alberts JC, Justin TA, Keeling NJ. Post-operative neutrophil-lymphocyte ratio predicts complications following colorectal surgery. Int J Surg 2007;5(1):27-30.
16. Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet 2001;357(9255):539-545.
17. Coussen LM, Werb Z. Inflammation and cancer. Nature 2002;420(6917):860- 867.
18. Miyamoto Y, Hosotani R, Doi R, Wada M, Ida J, Tsuji S, Kawaguchi M, Nakajima S, Kobayashi H, Masui T, Imamura M. Interleukin-6 inhibits radiation-induced apoptosis in pancreatic cancer cells. Anticancer Res 2001;21:2449-2456.
19. Hasselgren PO, Fischer E. Muscle cachexia: Current concept of intracellular mechanism and molecular regulation. Ann Surg 2001;233(1):9-17.
20. Brown KM, Domin C, Aranha GV, Yong S, Shoup M. Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. Am J Surg 2005;189(3):278-282.
21. Suzuki K, Aiura K, Ueda M, Kitajima M. The influence of platelets on the promotion of invasion by tumor cells and inhibition by antiplatelet agents. Pancreas 2004;29(2):132-140.
22. Schwarz RE, Keny H. Preoperative platelet count predicts survival after resection of periampullary adenocarcinoma. Hepatogastroenterology 2001;48(41):1493-1498.
23. House MG, Yeo CJ, Cameron JL, Campbell KA, Schulich RD, Leach SD, Hruban RH, Horton KM, Fishman EK, Lillemoe KD. Predicting resectability of periampullary cancer with three-dimensional computed tomography. J Gastrointest Surg 2004;8(3):280-288.
24. Maemura K, Takao S, Shinchi H, Noma H, Mataki Y, Kurahara H, Jinnouchi S, Aikou T. Role of positron emission tomography in decisions on treatment strategies for pancreatic cancer. J Hepatobiliary Pancreat Surg 2006;13(5):435-441.
25. Mortensen MB, Edwin B, Hunerbein M, Liedman B, Neilsen HO, Hovendal C. Impact of endoscopic ultrasonography (EUS) on surgical decision-making in upper gastrointestinal tract cancer: An international multicenter study. Surg Endosc 2007;21(3):431-438.